ASH Annual Meeting

ASH Annual Meeting

Interviews from the American Society of Hematology’s Annual Meeting


Anjali Advani, MD: Vadastuximab Talirine in Treatment-Naïve CD33-Positive AML

Monotherapy with vadastuximab talirine led to high response rates in older patients with acute myeloid leukemia who are considered unfit for intensive chemotherapy. Dr....

Martin Schrappe, MD: Attempting to Reduce Chemotherapy Burden in Children With ALL

Dr. Schrappe discusses results of the AIEOP-BFM ALL 2000 trial, presented as a plenary abstract at the 2016 ASH Annual Meeting.

Investigational Drug BLU-285 Shows Tolerable Safety, Early Clinical Activity in Patients With Advanced Systemic...

Data from an ongoing phase I trial of BLU-285, an oral inhibitor of KIT D816V, in patients with advanced systemic mastocytosis (SM) suggest that...

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.